PD-L1 >= 50%
About
Biomarker Type: Protein expression
Present: True
Marker: PD-L1
Unit: Tumor Proportion Score (TPS)
Equality: >=
Value: 0.5
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 >= 50% | Non-Small Cell Lung Cancer | Atezolizumab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR | Non-Small Cell Lung Cancer | Cemiplimab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Pembrolizumab | |
| Sensitivity (+) | PD-L1 >= 50% | Head and Neck Squamous Cell Carcinoma | Pembrolizumab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Cemiplimab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Carboplatin, Pemetrexed, Tislelizumab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Pemetrexed, Tislelizumab |